Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to ...

Hybrid closed-loop insulin delivery lowers risk for hypoglycemic coma and increases rate of ketoacidosis for young people with T1D.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its revolutionary Omnipod 5 ...

Growth hormone injections deliver a synthetic growth hormone to the body to treat hormone deficiencies and other health ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati ...

Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...

Apollo Health, a leading provider of clinically proven innovative health solutions for cognition, has partnered with Trifecta Nutrition, the nation's largest science-backed meal delivery service ...

Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplan ...

Insulet shows bullish trends with strong growth, favorable Wall Street ratings, and a 3.2:1 reward-risk ratio. Read more on ...

Family history increases diabetes risk, but these proven strategies can help you overcome genetic predisposition and prevent ...